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Background. The true frequency of hospital outbreaks of invasive group B streptococcal (iGBS; Streptococcus agalactiae) disease 
in infants is unknown. We used whole genome sequencing (WGS) of iGBS isolates collected during a period of enhanced surveil-
lance of infant iGBS disease in the UK and Ireland to determine the number of clustered cases.
Methods. Potentially linked iGBS cases from infants with early (<7 days of life) or late-onset (7–89 days) disease were identified 
from WGS data (HiSeq 2500 platform, Illumina) from clinical sterile site isolates collected between 04/2014 and 04/2015. We as-
sessed time and place of cases to determine a single-nucleotide polymorphism (SNP) difference threshold for clustered cases. Case 
details were augmented through linkage to national hospital admission data and hospital record review by local microbiologists.
Results. Analysis of sequences indicated a cutoff of ≤5 SNP differences to define iGBS clusters. Among 410 infant iGBS isolates, 
we identified 7 clusters (4 genetically identical pairs with 0 SNP differences, 1 pair with 3 SNP differences, 1 cluster of 4 cases with 
≤1 SNP differences) of which 4 clusters were uncovered for the first time. The clusters comprised 16 cases, of which 15 were late-
onset (of 192 late-onset cases with sequenced isolates) and 1 an early-onset index case. Serial intervals between cases ranged from 
0 to 59 (median 12) days.
Conclusions. Approximately 1 in 12 late-onset infant iGBS cases were part of a hospital cluster. Over half of the clusters were 
previously undetected, emphasizing the importance of routine submission of iGBS isolates to reference laboratories for cluster iden-
tification and genomic confirmation.
Keywords.  group B streptococcal disease; infant; cluster; healthcare-associated infection; whole genome sequencing.
Streptococcus agalactiae (group B Streptococcus [GBS]) is a 
leading cause of neonatal sepsis, currently classified as early-
onset disease (EOD) if infection occurs during the first 6 days 
of life or late-onset disease (LOD) if it develops 7–89  days 
after birth. These classifications correspond to the mode of 
transmission, with EOD resulting from vertical transmission 
during or just before birth and LOD often being attributed to 
horizontal transmission [1, 2]. Our understanding of trans-
mission after birth, however, remains very limited, the pre-
sumption being that GBS is acquired nosocomially or from a 
community source.
It has long been known that GBS can spread within hos-
pital nurseries [3]. A recent systematic review of invasive GBS 
(iGBS) outbreaks in healthcare settings showed that iGBS clus-
ters may occur more frequently than previously thought be-
cause intervals between consecutive cases can be long (up to 
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and microbiologists detecting unusual patterns [4]. The advent 
of genomic analysis allows us to identify and understand trans-
mission events [5], paving the way for control measures to be 
designed.
Our aim was to investigate clustering of cases of iGBS di-
sease in infants <90 days old in hospitals using whole genome 
sequencing data obtained from isolates submitted to Public 
Health England (PHE) from hospital and reference labora-
tories across the United Kingdom and Republic of Ireland 




We used existing whole genome sequence (WGS) data from 
clinical sterile site isolates (blood, cerebrospinal fluid [CSF]) 
from infants with invasive GBS (iGBS) disease received by 
the Public Health England (PHE) Respiratory and Vaccine 
Preventable Bacteria Reference Unit during a period of en-
hanced surveillance for cases of early (<7 days of life) and late-
onset (7–89  days) infant disease in the United Kingdom and 
Republic of Ireland (01/04/2014 to 30/04/2015) [6].
Identifying data for isolates from infant iGBS cases included 
patient name, date of birth, date of specimen collection, and 
name of referring hospital. Additional data (gestational age, 
birth weight, singleton/multiplet) were obtained from British 
Pediatric Surveillance Unit (BPSU) pediatrician reports sub-
mitted during the period of enhanced surveillance [6]. For 
clusters in England, patient identifiable data (date of birth, 
name) from sequenced isolates were sent to NHS Digital’s 
Demographic Batch Service (DBS) to obtain/confirm patient 
unique patient identifiers (NHS number) and obtain dates 
of death [7]. NHS numbers were then used to extract corre-
sponding hospital admission records from hospital episode 
statistics (HES; NHS Digital, copyright 2018) to create time-
lines for clusters. HES data provide clinical and organizational 
information, including diagnoses and procedures, dates of ad-
mission and discharge, admission method, and identity of care 
provider (hospital) [8]. Medical microbiologists at hospitals 
in England were contacted to determine whether there had 
been any suspicion of cross-infection between clustered cases 
at the time they occurred and whether cases had been in the 
same unit/on the same ward or in adjacent cots. Further in-
formation on clustered cases in Scotland, Wales, and Republic 
of Ireland was sought from enhanced surveillance study col-
laborators in each of these countries. Additional iGBS cases 
(±60  days of cluster cases) that either did not have isolates 
available for analysis or were separated from cluster cases by 
SNP differences above the cluster threshold were identified 
by reviewing enhanced surveillance data from hospitals with 
clusters.
SNP Difference Thresholds to Define iGBS Clusters
To determine an appropriate SNP-difference threshold for clus-
tered cases we used existing WGS data from clinical sterile 
site isolates from patients of all ages received by the PHE 
Respiratory and Vaccine Preventable Bacteria Reference Unit 
between January 2010 and May 2017. We reviewed distribu-
tions of SNP differences within clonal complexes from all iGBS 
sterile site isolates and initially applied a threshold of ≤10 SNP 
differences to identify potential clusters, with further explora-
tion up to 20 SNPs. An initial 10-SNP threshold was chosen as 
it exceeds the expected mutation rate (1–2 SNPs per genome 
per year) [9, 10] and the SNP differences (≤5) in published clus-
ters [5]. Information (specimen date, referring hospital, date of 
birth, name) accompanying specimens from infants (<90 days 
old) was examined to assess plausibility of cases being linked 
and to identify twin and mother-baby (early-onset neonatal) 
dyads. Combining case-cluster information with SNP differ-
ence distributions allowed us to identify a suitably discrimina-
tory threshold with which to define probable clusters for further 
epidemiological investigation.
Whole Genome Sequencing
All isolates had been sequenced using a HiSeq 2500 platform 
(Illumina; San Diego, CA, USA). Sequence types were deter-
mined using MOST and clonal complexes were determined 
from these profiles [11]. Reference genomes used for analysis 
were based on kmer-based distance estimates from MASH to 
identify representative complete genomes (see Supplementary 
File eTable 1) [12]. To remove SNPs from suspected regions of 
recombination, regions of high SNP density were removed from 
the analyses using GUBBINS (Genealogies Unbiased By recom-
Binations In Nucleotide Sequences) [13]. SNP matrixes for each 
clonal complex were produced using PHEnix (https://github.
com/phe-bioinformatics/PHEnix). Isolate sequences from this 
study are available via ENA (see Supplementary File eTable 2 for 
accession numbers). The age and sex distribution for the iso-
lates is shown in Supplementary File eTable 3.
Ethics
All data were collected within statutory approvals granted to 
the respective public health authorities in the United Kingdom 
and Ireland for infectious disease surveillance and control. 
Information was held securely and in accordance with the Data 
Protection Act 2018 and Caldicott guidelines.
Role of the Funding Source
This study had no specific funding.
RESULTS
SNP Difference Thresholds to Define iGBS Clusters
Whole genome sequence data were available for 754 unique 
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between 2010 and 2017 including 410 infant iGBS isolates 
from the 13-month period of enhanced surveillance between 
April 2014 and April 2015. The distributions of SNP differences 
across each GBS clonal complex (CC) are shown in Figure  1 
(see also Supplementary eFigure S1  & eFigure S2). These 
show clear separation within each CC between pairs of iso-
lates that are genetically identical (0 SNP differences) or similar 
(≤5 SNPs) and all other pairs of isolates. Just 2 pairs fell between 
5 and 10 SNP differences, each with an 8 SNP difference; these 
are described below.
In total, there were 17 potential clusters of isolates involving 
an infant with <10 SNP differences between isolates (Figure 2). 
These potential clusters included four mother-baby (early-
onset) pairs and 4 twin pairs (2 early-onset pairs, 2 late-onset 
pairs; see Supplementary File eTable 4). The 9 remaining po-
tential clusters comprised 2 pairs separated by 8 SNPs between 
cases, 1 pair with 3 SNP differences, 3 identical pairs (0 SNP 
difference), and 3 serial clusters (all ≤1 SNP difference). Raising 
the initial threshold to ≤20 SNPs did not reveal any additional 
clusters involving infants. Of the 2 pairs with 8 SNP differences: 
1 was a pair of early-onset cases (at 0 and 1  day of life) and 
therefore not plausibly attributable to horizontal transmission 
(samples were 114 days apart); the other comprised an early-
onset case followed 6  months (193  days) later by a late-onset 
case in the same hospital. No clusters were identified under the 
initial <10 SNP-difference threshold involving children older 
than 90 days or adults (other than the mother-infant pairs).
Infant iGBS Clusters
Using a cutoff of ≤5 SNP differences to define an iGBS cluster, 
7 clusters (16 cases in total) were identified in the United 
Kingdom and Ireland during the enhanced surveillance pe-
riod (Table  1). Six of the 7 clusters involved pairs of cases, 
with the remaining cluster comprising 4 cases. Serial intervals 
ranged from 0 to 25  days for pairs with ≤1 SNP difference; 
the cases in the pair with 3 SNP differences occurred 59 days 
apart. Of the 7 clusters, 4 had not been identified by the hos-
pitals as potential clusters. The other 3 were known serial clus-
ters that occurred in a neonatal intensive care unit (NICU) 
comprising: an initial cluster of 4 serotype V late-onset cases 
over a 4-week period; a second cluster, 9  months later, of 
2 serotype III late-onset cases 13  days apart; a third cluster, 
10 months after the first cluster, comprising twins with late-
onset disease (12 days apart) preceded 9 days earlier by an in-
fant with a positive rectal swab, which differed from the twin 
cases by 5 SNPs. Our analysis replicated exactly the previously 
reported SNP differences [5].
Previously Undetected Clusters
One cluster was identified in Ireland, which comprised a pair 
of pre-term LOD cases 9 days apart with 0 SNP differences and 
linked to the same hospital (Table 1). No further timeline in-
formation was available for this cluster. The remaining clusters 
occurred in hospitals in England as described below, with time-
lines shown in Figure 3.
Cluster A
This cluster (serotype III, CC17, ST17, 3 SNP differences) com-
prised 2 late-onset cases occurring 59 days apart. Both infants 
were born at full term in the same hospital (A) 66 days apart 
and both were discharged home 2 days after birth. Case 1 was 
admitted to hospital A via A&E at 19 days of life, and GBS was 
isolated from a blood sample taken on the day of admission; the 
infant was discharged home 16 days later. Forty-three days after 
case 1 was discharged, case 2 was admitted for “septic shock” 
to a different (but geographically close) hospital (B) via A&E at 
12 days of life. Medical records at the hospital (A) did not indi-
cate any suspicion of a link between the cases at the time they 
occurred. Case 1 had been readmitted to hospital A via A&E 
30 days later for “gastro-oesophageal reflux disease without oe-
sophagitis,” staying for 2  days before being discharged home. 
The second day of this admission coincided with the birth of 
case 2 in hospital A, but case 1’s readmission was to a general 
pediatric ward 1 floor above the delivery suite where case 2 
was born. The postnatal and general pediatric wards were usu-
ally staffed by different teams, and no evidence was found to 
suggest that case 2 was transferred from the postnatal ward to 
the general pediatric ward. No other cases reported during the 
enhanced surveillance period could be linked to the cases in 
cluster A  based on time (±60  days from either case) or SNP 
Figure 1. Distributions of SNP differences between any pair of isolates below 51 
SNPs across each iGBS clonal complex in isolates received by the PHE Respiratory 
and Vaccine Preventable Bacteria Reference Unit, 2010–2017 (N  =  754). 
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threshold; the closest case in time was a late-onset case 95 days 
after case 2 with 115 SNP differences.
Cluster B
This cluster (serotype III, CC17, ST17, 0 SNP difference) com-
prised an early-onset case (case 1) followed 12 days later by a 
late-onset case (case 2), both born at the same hospital. Case 2 
was born preterm (at 29 weeks) 24 days before the birth of case 
1 and was still hospitalized at the time of case 1’s birth. Case 1 
(full term) had GBS at 0 days of life and was discharged home 
after 9 days. Case 2 developed late-onset GBS at 36 days of life 
whilst still in hospital, was discharged home on day 57, but re-
admitted 2 days later via A&E with “streptococcal meningitis” 
(GBS was isolated from a second blood sample taken on the 
day of readmission, no WGS data available), leading to a fur-
ther hospital stay of 15 days’ duration before being discharged 
home. Bed management system records at the hospital showed 
that there was a period of 4 days when both cases were in the 
same bay on the special care baby unit. No other cases reported 
during the enhanced surveillance period could be linked to the 
cases in cluster B; the closest cases in time occurred 58 days and 
70 days after case 2, the first a late-onset case with no isolate, the 
second a late-onset case with 373 SNP differences.
Cluster C
This cluster (serotype Ia, CC23, ST23, 0 SNP difference) com-
prised two late-onset cases occurring 25 days apart born at the 
same hospital. Case 1 was preterm (29 weeks) and hospitalized 
from birth (for 73 days), with GBS occurring at 26 days of life. 
Case 2 was 1 of 2 preterm twins (30 weeks) and was born during 
the hospital stay of case 1; late-onset GBS developed at 17 days 
of life. Hospital records showed that both cases were nursed on 
the same ward. No late-onset cases with the same serotype were 
reported within 6 months of the 2 cases in cluster C.
DISCUSSION
This is the first population-wide study to make a systematic as-
sessment of infant iGBS clusters in hospitals and to determine 
a genomic threshold for identifying such clusters. We found 
over half of genomic clusters were previously undetected. All 
unreported clusters were epidemiologically plausible. Of the 
16 cases involved in these clusters, 3 died, including 1 secondary 
case. Although we cannot determine the preventability of these 
infections, our findings should direct further public health re-
search to identify opportunities for prevention.
To date, 30 hospital GBS clusters have been documented 
across 11 countries worldwide [4]. Among them were 4 clus-
ters that occurred in a neonatal unit in England, 3 of which 
fell within the period of enhanced surveillance in the United 
Kingdom and Ireland. These 3 clusters were independently 
identified in our study through our assessment of genomic var-
iation, validating the methodology (SNP thresholds) developed 
during this study [5].
Figure 2.  Flowchart showing data sources and linkage used to determine SNP difference thresholds for iGBS clusters and to identify iGBS clusters during a period of 
enhanced surveillance for cases of EOD (<7 days of life) and LOD (7–89 days) in the United Kingdom and Ireland, 2014/2015. Abbreviations: EOD, early-onset disease; HES, 
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Our study confirms that links between infant GBS cases will 
escape detection without use of genomic analysis. We have also 
provided further evidence that serial intervals between linked 
cases can be quite long (≥2 weeks), a factor which potentially 
hinders detection of infant GBS clusters in healthcare settings 
and therefore needs to be brought to the attention of health-
care professionals [4]. We also note that the second case in our 
cluster A was admitted with iGBS to a different hospital, an ad-
ditional obstacle to detection. Taken together, the implication of 
these factors is that our understanding of late-onset infant GBS 
attributable to nosocomial transmission remains very limited 
and in need of prospective genomic studies.
The 2 previously unreported clusters in our study where one 
preterm case had a prolonged period of hospitalization (clusters 
B and C) comprised case pairs with genetically identical isolates 
and serial intervals of 12 and 25 days. In the other previously 
unreported cluster (A), the 2 cases were term infants who were 
discharged home prior to late-onset of GBS, and the 3-SNP dif-
ference between the isolates is consistent with the longer interval 
between the 2 cases (59 days). In this cluster, horizontal trans-
mission could have occurred through environmental contami-
nation, which persisted from the time of birth of the index case 
or when the index case was readmitted for gastro-oesophageal 
reflux. This readmission coincided with the birth of the second 
case, whose late-onset GBS developed 12 days later. Horizontal 
transmission could have occurred if the index case was still 
colonized with the same GBS strain (data not available) and 
if there was a transmission route via staff and/or equipment; a 
third possibility is that both cases arose from persistent carriage 
of GBS by a healthcare worker. We did not have sufficient infor-
mation to determine whether the readmitted infant stayed in 
proximity to the subsequent case or was cared for by the same 
personnel.
The next most closely related cases in our study occurred in 
2 clusters where the case pairs within each cluster differed by 
8 SNPs. The epidemiological plausibility of these 2 clusters was 
very weak: 1 comprised 2 early-onset cases 114 days apart; the 
other 2 late-onset cases 193 days apart. We did not find any clus-
ters with 4–7 or 9 SNP differences to investigate epidemiological 
plausibility, but our results suggest that ≤5 SNP differences is a 
reasonable threshold for potentially linking infant GBS cases.
The main strength of our study is that it used data and iso-
lates collected during a period of prospective, active national 
surveillance of invasive GBS disease in infants [6]. During this 
time, the British Pediatric Surveillance Unit (BPSU) facilitated 
reporting of iGBS cases by pediatricians, whereas PHE triangu-
lated case data with routine microbiology and reference labora-
tory data. The main limitations of our study were that isolates 
were submitted for only half the number of reported cases 
(410/856); therefore, some clusters may have escaped detec-
tion. Also, although the BPSU-supported study used multiple 
sources to maximize case ascertainment, this does not guar-
antee that all cases were reported, and infants with probable 
(culture-negative) invasive GBS were not included.
Epidemiological investigation in our study was limited to 
contacting consultant microbiologists to obtain information 
retrospectively. Detailed epidemiological data might have al-
lowed us to identify mechanisms of transmission or sources 
of infection. However, we note that 2 of the 3 clusters reported 
previously by Jauneikaite et al were identified as part of a pro-
spective within-hospital study, which indicated deficient breast 
pump hygiene as a possible route of infection but was otherwise 
Table 1. Characteristics of Cases in Infant Invasive Group B Streptococcal (iGBS) Disease Clusters in United Kingdom and Ireland Identified by Genomic 
Analysis from Isolates Collected During a Period of Enhanced Surveillance (04/2014–04/2015)
Country








Singleton or  
Multiplet
Age at Onset of iGBS 
(days) Serial Interval (days)
Ireland Ib (ST8, CC10) 1 … 25 Singleton 22 …
  2 0 SNPs 24 Singleton 74 9
England 
(cluster A)
III (ST17, CC17) 1 … 40 Singleton 19 …
 2 3 SNPs 40 Singleton 12 59
England 
(cluster B)
III (ST17, CC17) 1 … 40 Singleton 0 …
 2 0 SNPs 29 Singleton 36 12
England 
(cluster C)
Ia (ST23, CC23) 1 … 29 Singleton 26 …
 2 0 SNPs 30 Twin 17 25
Englanda V (ST1, CC1) 1 … 27 Twin 12 …
  2 ≤1 SNP 24 Singleton 9 11
  3 ≤1 SNP 26 Singleton 44 17
  4 ≤1 SNP 29 Singleton 51 0
Englanda III (ST17, CC17) 1 … 39 Singleton 39 …
  2 0 SNPs 32 Singleton 32 13
Englanda Ib (ST139, CC1) 1 … 25 Twins 46 …
  2 0 SNPs 25 58 12
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unable to identify mechanisms or sources of cross-infection. 
This difficulty was reflected in our systematic review of iGBS 
outbreaks in healthcare settings, in which half of the 17 in-
cluded studies suggested lapses in infection control, including 
inadequate disinfection of equipment and surfaces, and close 
proximity of cots compounded by factors such as crowding and 
high patient-to-nurse ratio, but none were unable to provide 
microbiological evidence of sources or routes of cross-infection 
or whether outbreaks were propagated rather than being spread 
from a point source [4].
Our linked data analysis only allowed us to link to the infant’s 
birth record within the hospital episode database (mother’s and 
baby’s records are not routinely linked for data protection reasons), 
and the enhanced surveillance system did not record maternal 
data. We were therefore unable to enrich the reported data with 
information about the mother of each case, including maternal 
GBS status and receipt of intrapartum antibiotic prophylaxis.
During the period of enhanced surveillance covered by our 
study the predominant serotypes were III (60%) and Ia (17%) 
[6]. Five serotypes (Ia, Ib, II, III, V) accounted for 94% of all 
serotyped isolates, and most serotype III (74%) and Ia isolates 
(74%) belonged to sequence types ST17 and ST23, respectively. 
Our results reflect these common serotypes, and although we 
cannot be certain that our analysis did not miss iGBS clusters 
of other serotypes, these would need to have markedly different 
SNP-difference distributions.
Figure 3. Time lines for previously undetected infant iGBS clusters showing dates of birth, iGBS onset, and hospital admission/discharge. Abbreviation: iGBS, invasive 
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Of the 13 late-onset cases that we identified in England (8 in 
3 clusters reported by Jauneikaite et  al plus 5 in 3 previously 
unreported clusters), 7 are plausibly attributable to horizontal 
transmission from a preceding early or late-onset case and 1 (the 
first case in the twin case pair reported by Jauneikaite et al) from 
a colonized infant. Isolates from these 8 cases were among 130 
sequenced isolates with known time of disease onset collected 
during the period of enhanced surveillance. Therefore, we can 
estimate that as many as 8/130 (6%) of late-onset cases arose 
through nosocomial transmission. This denominator includes 
cases admitted from home: the proportion of cases occurring 
within an intensive or special care unit that are attributable to 
nosocomial transmission will probably be higher.
Given the global burden and long-term sequelae of infant 
iGBS disease and the absence of measures to prevent late-
onset disease [14–16], further research is warranted to better 
understand transmission routes for late-onset iGBS to in-
form strategies for prevention, including the likely clinical 
and cost-effectiveness of GBS vaccination of mothers and the 
wider population [17–19]. Consideration needs to be given to 
whether additional infection control precautions are warranted, 
although evidence suggests that cross-infection occurs when 
existing measures fail [4]. In the meantime, clinicians should 
maintain a high index of suspicion for potential GBS clusters 
and ensure routine submission of isolates to a reference labora-
tory to facilitate future investigation and confirmation through 
genomic analysis.
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